PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Achondroplasia

Drugs in development · updated 30 October 2026

Achondroplasia: drugs in development

As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 8 drugs for achondroplasia. 4 are experimental, that is not yet approved in the United States.

13Active trials
4Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
BMN 333II–III1NCT07441876
KK8398III1NCT06926491
ABSK061I–II1NCT07297875
TYRA-300II1NCT06842355

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
NavepegritideTransCon CNP, Yuviwel®II–III4NCT05929807
VosoritideBMN 111, Voxzogo®II–III4NCT07441876
InfigratinibTruseltiq®, Febseltiq®II2NCT05145010
LonapegsomatropinSkytrofa (previously Lonapegsomatropin Ascendis Pharma)®II1NCT06433557

Sorted by most advanced phase and number of active trials.

All 8 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000130 “Achondroplasia”.

ItalianoFrançaisDeutsch